OSE Immunotherapeutics Reports On Its 2022 Combined General ...| MENAFN.COM

Saturday, 25 June 2022 01:04 GMT

OSE Immunotherapeutics Reports On Its 2022 Combined General Shareholder's Meeting


(MENAFN- GlobeNewsWire - Nasdaq)

NANTES, France, June 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders' Meeting were approved as proposed by OSE Immunotherapeutics' Board of Directors.

The results of each resolution voted on can be found on the Company's website in the“Investor – General Shareholders' Meeting” section: .

In total, the shareholders who participated in person, by proxy to the chairman, by proxy to a third party or by postal vote, owned 8,149,700 shares representing 12,185,924 votes, i.e. 44.14% of the capital and 66% of the voting rights.

The shareholders approved the annual and consolidated financial statements as of December 31, 2021. They also approved the renewal of the term of office as director of Maryvonne Hiance, Didier Hoch and Nicolas Poirier (director representing the employee shareholders), which expired at this General Meeting, for three years. They also ratified the appointment of Alexandre Lebeaut as a new independent Director until the date of the present Shareholders' Meeting and renewed his mandate as director for three years.

ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile:

Immuno-Oncology first-in-class products

  • Tedopi® (innovative neoepitope combination): the Company's most advanced product; positive results for Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure.
    Other ongoing combination trials sponsored by cooperative clinical research groups in oncology:
    Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.
    Phase 2 in ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor ARCAGY-GINECO.
    Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT.
  • BI 765063 (OSE-172, anti-SIRPα mAb on CD47/SIRPα pathway): developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy and in combination with ezabenlimab (PD-1 antagonist); ongoing expansion Phase 1; BI sponsored international phase 1b clinical trial ongoing in combination with ezabenlimab alone or with other drugs in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC).
  • OSE-279 , anti-PD1 – advanced preclinical stage.
  • BiCKI® : bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target (for example: BiCKI®-IL7, preclinical stage) to increase anti-tumor efficacy.

Immuno-Inflammation first-in-class products

  • OSE-127/S95011 (humanized monoclonal antibody antagonist of IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; ongoing Phase 2 in ulcerative colitis (sponsor OSE) and ongoing Phase 2a in Sjögren's syndrome (sponsor Servier).
  • FR104 (anti-CD28 monoclonal antibody): licensing partnership agreement with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2 in renal transplant (sponsored by the Nantes University Hospital); Phase 1 ongoing in the US (sponsor Veloxis Pharmaceuticals, Inc.); Phase 2 planned in an autoimmune disease indication.
  • OSE-230 (ChemR23 agonist mAb): preclinical stage therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

CoVepiT : a prophylactic second-generation vaccine activating cytotoxic T lymphocytes against COVID-19, developed using optimized epitopes from SARS-CoV2 viral proteins, epitopes non impacted by multi-variants. Shows good tolerance and very good level of T cell immune response. In clinical testing, a long-term memory response was confirmed at 6 months.

Click and follow us on Twitter and Linkedln

Contacts

OSE Immunotherapeutics
Sylvie Détry

+33 153 198 757
Investor Relations
Thomas Guillot

+33 607 380 431
Media
U.S. Media: LifeSci Communications
Darren Opland, Ph.D.

+1 646 627 8387
French Media: FP2COM
Florence Portejoie

+33 607 768 283

Guillaume van Renterghem – LifeSci Advisors

+41 76 735 01 31

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
These forward-looking statements include statements typically using conditional and containing verbs such as“expect”,“anticipate”,“believe”,“target”,“plan”, or“estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2022, including the annual financial report for the fiscal year 2021, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.




MENAFN23062022004107003653ID1104422777


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.